Table 6.
Liver function tests at 1 month after treatment
| Parameters | CSM-TACE group (N=171) | cTACE group (N=164) | P-value |
|---|---|---|---|
| ALT (u/L) | 37.1 (21.7–57.0) | 31.0 (21.1–50.8) | 0.105 |
| AST (u/L) | 53.5 (33.5–81.4) | 44.6 (30.9–70.3) | 0.110 |
| ALP (u/L) | 144.0 (108.1–193.0) | 120.0 (84.0–160.0) | 0.005 |
| TB (umol/L) | 17.4 (13.5–24.1) | 15.2 (11.0–22.2) | 0.031 |
| ALB (g/L) | 35.1 (30.0–38.6) | 35.8 (31.4–39.6) | 0.287 |
| TP (g/L) | 69.1 (63.4–73.5) | 67.4 (63.1–73.0) | 0.591 |
| TBA (I/L) | 10.7 (5.8–27.0) | 9.5 (5.2–22.6) | 0.474 |
Notes: Data was presented as median (25th–75th quantiles) or count (%). Comparison between the two groups was determined by Wilcoxon rank sum test. P-value <0.05 was considered significant, and the significant results were shown in boldface.
Abbreviations: CSM-TACE, transarterial chemoembolization with CalliSpheres® microspheres; cTACE, conventional transarterial chemo-embolization; ALT, alanine aminotransferase; AST, aspartate aminotransferase; TB, total bilirubin; ALB, albumin; TP, total protein; TBA, total bile acid.